Fig. 3From: Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysisSubgroup survival analysis. Survival analysis under different pembrolizumab dose – 3A: PFS; 3B: OS. Survival analysis under cetuximab use – 3C: PFS; 3D: OS. Survival analysis under different clinical response states – 3E: PFS; 3F: OS. Survival analysis under different status of recurrence – 3G: PFS; 3H: OSBack to article page